Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ensysce Biosciences (ENSC) Research & Development (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Research & Development for 6 consecutive years, with $3.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development rose 74.78% to $3.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $10.6 million, a 87.03% increase, with the full-year FY2024 number at $7.2 million, down 4.85% from a year prior.
  • Research & Development was $3.0 million for Q3 2025 at Ensysce Biosciences, up from $1.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $6.4 million in Q4 2022 to a low of $284378.0 in Q1 2021.
  • A 5-year average of $2.4 million and a median of $1.9 million in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: soared 1046.61% in 2022, then crashed 69.05% in 2023.
  • Ensysce Biosciences' Research & Development stood at $2.2 million in 2021, then soared by 194.44% to $6.4 million in 2022, then tumbled by 65.34% to $2.2 million in 2023, then skyrocketed by 70.31% to $3.8 million in 2024, then dropped by 22.29% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Research & Development are $3.0 million (Q3 2025), $1.9 million (Q2 2025), and $1.9 million (Q1 2025).